Skip to main content
Current Genomics logoLink to Current Genomics
. 2011 May;12(3):169–179. doi: 10.2174/138920211795677895

Genetics of Obesity: What have we Learned?

Hélène Choquet 1, David Meyre 2,*
PMCID: PMC3137002  PMID: 22043165

Abstract

Candidate gene and genome-wide association studies have led to the discovery of nine loci involved in Mendelian forms of obesity and 58 loci contributing to polygenic obesity. These loci explain a small fraction of the heritability for obesity and many genes remain to be discovered. However, efforts in obesity gene identification greatly modified our understanding of this disorder. In this review, we propose an overlook of major lessons learned from 15 years of research in the field of genetics and obesity. We comment on the existence of the genetic continuum between monogenic and polygenic forms of obesity that pinpoints the role of genes involved in the central regulation of food intake and genetic predisposition to obesity. We explain how the identification of novel obesity predisposing genes has clarified unsuspected biological pathways involved in the control of energy balance that have helped to understand past human history and to explore causality in epidemiology. We provide evidence that obesity predisposing genes interact with the environment and influence the response to treatment relevant to disease prediction.

Keywords: Biologic pathways, disease prediction, food intake, gene x environment interactions, genetic continuum, Mendelian randomization, obesity, positive selection.

INTRODUCTION

In 2001, six genes were linked to monogenic human obesity and no common variants were reproducibly associated with polygenic obesity. By 2008, progress in the field led to the discovery of eight monogenic genes and four polygenic genes (FTO, PCSK1, MC4R, CTNNBL1) from associated studies at the genome-wide level of significance. The recent emergence of the genome-wide association studies (GWAS) has led to further breakthroughs in gene identification and now nine loci are recognized to be involved in Mendelian forms of obesity along with 58 loci contributing to polygenic obesity. In this review, we will discuss what we have learned from this recent progress in elucidating the molecular basis of obesity. We propose an overlook of major lessons learned from 15 years of research in the field of the genetics and obesity.

GENETICS OF OBESITY: LESSONS LEARNED

A Continuum between Monogenic and Polygenic Obesity

A striking observation is the existence of a partially overlapping continuum between monogenic and polygenic forms of obesity. Currently, four genes (MC4R, PCSK1, POMC and BDNF) have been involved in the two conditions, and this list is likely to grow in the upcoming years. This continuum is not specific to obesity, since one-fifth of the loci that were found to be associated with complex disease traits include a gene that is mutated in a corresponding single-gene disorder [1]. The case of MC4R is illustrative of this point of view. Whereas more than 150 loss-of-function coding mutations have been associated with monogenic obesity [2], two infrequent gain-of-function coding polymorphisms (V103I and I251L) have been associated with the protection from obesity [3, 4]. Furthermore, a SNP located 188 kb downstream of the MC4R coding sequence has been associated with a modest increase in the risk for obesity [5].

Dickson et al. [6] have recently proposed the synthetic association hypothesis: GWAS signals of common non-functional SNPs outside of coding regions may be the result of a combination of rare/coding functional variants with stronger effects given that these rare variants arose on a haplotype which is tagged by the common SNP. This hypothesis, if true, may explain why some genes are associated with monogenic and polygenic forms of the same disease. A careful investigation of MC4R has therefore invalidated the synthetic association hypothesis at this locus, and supports the concept of an independent contribution of both rare and common variants at the same locus for obesity risk [7].

Another lesson of the observed continuum between monogenic and polygenic forms of obesity is that GWAS-derived novel loci should be considered as highly relevant candidate genes for monogenic obesity, especially if additional arguments in humans or animal models strengthen the candidacy of the gene. The SH2B1 gene is for instance an interesting candidate as SNPs at the SH2B1 locus are associated with BMI by GWAS [8], rare deletions including SH2B1 are associated with a Mendelian form of obesity [9, 10] and inactivation of SH2B1 in mice leads to hyperphagia, leptin resistance and obesity [11]. However, notable exceptions have been reported for other promising candidate genes. For example, FTO is the major contributor to polygenic obesity [12] and mice down or over-expressing FTO are resistant or prone to develop obesity [13, 14]. However, heterozygous loss-of-function mutations in FTO are found in both lean and obese subjects and do not contribute to monogenic obesity [15].

Obesity is an Inherited Disorder of Central Regulation of Food Intake

Defects in eight genes involved in the neuronal differentiation of the paraventricular nucleus and in the leptin/melanocortin pathway, have been shown to lead to human monogenic obesity with hyperphagia as a common feature [16]. Recent progress in the elucidation of polygenic predisposition to obesity also points to a key role of the central nervous system in body weight regulation [17].

The association of the two major contributors to polygenic obesity (SNP rs17782313 near MC4R and SNP rs1421085 / rs9939609 in FTO) [5, 18, 19] with food intake / food behavior-related endophenotypes has been well documented in the literature. The obesity predisposing FTO variant was associated with increased total and fat dietary intake in children [20, 21] as well as in adults [22]. The obesity risk variant was also associated with diminished satiety and / or increased feeling of hunger in children [23] and in adults [24]. The obesity predisposing SNP variant near MC4R was associated with increased feeling of hunger [25, 26], increased snacking [25], decreased satiety [26], and increased total, fat and protein energy intake [25, 27], the effects of the variant on food-related parameters being observed both in children and adults. Bauer et al. [28] recently reported evidence for an association of additional obesity genes recently identified by GWAS (SH2B1, KCTD15, MTCH2, NEGR1, BDNF) with dietary intake and nutrient-specific food preference.

The genetic dissection of monogenic and polygenic forms of obesity delineate it as an inherited disorder of central regulation of food intake [16]. This is in line with the fact that food intake-related parameters are heritable [29] and are strongly correlated to body mass index [30].

Gene Identification Illuminates New Pathways Involved in Energy Balance

A primary goal of human genetic agnostic approaches such as GWAS is to improve our understanding of the biologic pathways underlying polygenic diseases and traits [1]. A majority of obesity loci identified by GWAS studies do not harbor genes with clear connections to the biology of body weight regulation [12], reflecting our limited understanding of the biology of obesity in contrast with other complex traits (such as autoimmune diseases or lipid levels). Recent progress in genetic dissection of obesity predisposition provides the opportunity to explore novel and sometimes unsuspected pathways related to this condition.

The FTO story constitutes a textbook case: the FTO gene has been cloned in mice in 1999 [31] but the “buzz” around this gene started after the publication of two seminal genetic studies demonstrating a link between FTO common gene variation and human obesity in 2007 (at this time, FTO was a gene of unknown function in an unknown pathway) [18, 19]. More than 400 articles have been published since increasing our understanding of the mechanisms linking this gene to the pathophysiology of obesity. Follow-up studies have confirmed the association between FTO and obesity-related phenotypes not only in populations of European ancestry but also in African, Asian, South Asian, South American and Pima Indian populations [32-36].

Complete FTO deficiency in humans is associated with an autosomal-recessive lethal syndrome including growth retardation, multiple malformations and premature death, indicating that FTO is essential for normal development of the central nervous and cardiovascular systems in human [37]. Loss of one functional copy of FTO in humans was not associated with a specific phenotype, and heterozygous loss-of-function mutations are found both in lean and in obese subjects [15]. Complete or partial inactivation of the Fto gene in mice protects from obesity [13, 38] whereas over-expression of Fto in mice increases food intake and results in obesity [14]. These data have provided direct functional evidence that FTO is a causal gene underlying obesity, and suggest the intronic variant in FTO may increase obesity risk in humans through FTO gain of expression. Expression studies in wild-type rodents have shown that FTO is highly expressed in the hypothalamus and is regulated by feeding and fasting [39, 40]. Over- or down-expression of Fto in the hypothalamus modulates food intake in mice possibly through the leptin / STAT3 signalling pathway [40, 41].

Bioinformatics, in vitro and crystallography studies have shown that FTO is a single-stranded DNA demethylase and is involved in nucleic acid repair or modification processes [39, 42]. The link between this genes’ ability to modify nucleic acids and body weight regulation may be puzzling, but may relate to epigenetic processes. FTO has been proposed as a transcriptional coactivator that enhances the transactivation potential of the CCAAT / enhancer binding proteins (C/EBPs) from unmethylated as well as methylation-inhibited promoters, suggesting a role in the epigenetic regulation of the development and maintenance of fat tissue [43]. In line with this hypothesis the fact that the FTO intronic SNP is associated with a distinct methylation pattern of a 7.7 kb region at the FTO locus, that includes a highly conserved non-coding element validated as a long-range enhancer [44].

The study of FTO illustrates how human genetic “hypothesis free” approaches can be a catalyst to approaches in functional genomics and the same integrative approach can be applied to other obesity-associated genes markedly increasing our understanding of the physiology of obesity in the upcoming years.

Obesity Genes to Explore Causality in Epidemiology: The Mendelian Randomization Approach

Spurious associations in observational epidemiological studies are commonly caused by confounders due to social, behavioral, or environmental factors and can therefore be difficult to control. They may also be due to reverse causation, in which the phenotypic outcome subsequently influences an environmental exposure such that it is wrongly implicated in the pathogenesis. Genetic epidemiology can be used to uncover more thoroughly and more accurately causal factors underlying common diseases or complex traits. The epidemiologic approach with the most promise is often referred to as Mendelian randomization [45]. The principle is to use genetic variation as a randomly redistributed variable among populations to control for unobserved confounding variables in an observational setting [45].

This approach has been successfully used in the obesity arena following the identification of FTO as a major contributor to polygenic variation [18]. The Frayling et al. [18] seminal study represents in fact a good example of Mendelian randomization since a BMI-dependent association between FTO and type 2 diabetes mellitus (T2D) has been observed, suggestive of a causative relationship between weight gain and subsequent T2D development. The same approach, when applied to 12 obesity gene variants, confirmed that the genetic predisposition to obesity leads to an increased risk of developing type 2 diabetes, which is completely mediated by its effect on BMI [46]. The FTO genotype has also been used to confirm the findings of observational epidemiology and a causal relationship between BMI increase and altered glucose [47], insulin resistance [48], lipid [47] and blood pressure values [49]. The causal association between increased BMI and increased level of inflammation [50] or increased bone mass [51] has also been confirmed, and the use of FTO SNP as a randomly redistributed variable strengthened the evidence of a causal link between a BMI increase and an increased risk of atherosclerosis [52], cardiovascular diseases [53], endometrial or kidney cancers [54, 55] and a decreased risk of lung or prostate cancers [54, 56].

Genes are Useful to Understand Past Human History

The human genome contains hundreds of regions whose pattern of genetic diversity indicate recent positive natural selection (positive natural selection is the force that drives the increase in prevalence of advantageous traits like de novo mutations) [57]. Adaptation to new environments, infectious diseases and changes in diet may explain why certain mutations have been positively selected in human populations [58]. The transition to agriculture has introduced new adaptive pressures that shaped our genome to an increased fat storage efficiency including exposure to regular famine, adaptation to a variety of local niches favoring population-specific adaptations and the development of social hierarchies which predispose to differential exposure to environmental pressures [59]. The “thrifty genotype” hypothesis, proposed by Neel in 1962 [60], was recently confirmed for several obesity genes that show evidence of positive selection across human history. For example, the rs4988235 functional variant in the lactase (LCT) gene confers lactase persistence and carriers of at least one T allele, are able to digest the milk sugar lactose across their life span (the activity of the lactase enzyme in intestinal cells declines during childhood in non-carriers) [61, 62]. The selective advantage of lactase persistence in milk-producing dairy farming populations has induced positive selection signatures regionally for the LCT rs4988235 T variant strongly related to events of cattle domestication [63, 64]. A North to South gradient has been observed for the LCT rs4988235 SNP in Europe [63] as well as local geographic population substructures among provinces in the United Kingdom [65]. In line with its proposed selective advantage, the LCT rs4988235 T variant has been consistently associated with higher milk consumption [66] and with higher body mass index [67] in European populations.

Interestingly, three functional coding non-synonymous variants in the LEPR (Lys109Arg), ADRB3 (Trp64Arg) and BDNF (Val66Met) genes previously associated with BMI [8, 68, 69], harbor patterns of strong positive selection in population genetic studies [70-72]. Recently, analysis of GWAS-derived obesity gene variants provided evidence of positive natural selection at the FTO, NEGR1, SH2B1 and FAIM2 loci [73, 74].

The evolutionary history of the MC4R obesity locus has been well documented in the literature. The melanocortin 4 receptor coding sequence has been remarkably conserved in structure and pharmacology for more than 400 million years, implying that this receptor participated in vital physiological functions early in vertebrate evolution [75]. There is a significant paucity of diversity at the MC4R gene in humans in comparison with primates [76]. The coding region of MC4R has been subject to high levels of continuous purifying selection that increased threefold during primate evolution [76]. Finally, there is a tendency for non-synonymous mutations that impact MC4R function to be located at amino acid positions that are highly conserved during the 450 million years of MC4R evolution in vertebrates and subject to very strong purifying selection [76].

Genes Interacting with Environments

As trends over the past several decades suggest an environmental influence on BMI, many researchers have focused on the identification of specific environmental factors that interact with genetic predisposition to obesity. They based their investigations on epidemiological data showing that physical activity, diet, educational status, age, gender and ethnicity among others modulate the risk for obesity [77].

Recent literature provides firm evidence that genetic susceptibility to obesity can be blunted in part through physical activity. Thirteen independent studies reported an interaction between the FTO obesity risk genotype and physical activity on BMI variation or obesity risk including adults as well as adolescents [78-81]. Similar results were obtained for a genetic predisposition score combining the information of 12 obesity-associated SNPs, and a high level of physical activity associated with a 40% reduction in the genetic predisposition to common obesity [82].

There is also growing evidence that dietary habits interact with genes to modulate predisposition to obesity. Three studies suggest that a high fat diet can amplify the effect of the FTO genotype on obesity risk [79-81]. An interaction between the Apolipoprotein A-II (APOA2) -265T>C SNP and high-saturated fat in relation to BMI and obesity has been reported in five independent populations [83, 84]. Interestingly, this SNP was not identified by recent GWAS approaches, suggesting that some associations restricted to specific environments may be missed in global analyses.

Epidemiological studies have shown that people with a low level of education are more likely to develop obesity [85]. However, very few studies have investigated the impact of genes on the association between education and obesity-related variables. This well-established negative association between BMI and educational status was not found in MC4R loss-of function mutation carriers, although a significant relationship was seen in MC4R non-mutation carriers of the corresponding pedigrees [2]. These results suggest that a high level of education has no protective effect on obesity risk in presence of MC4R pathogenic mutations. On the contrary, a significant gene x education interaction has been found for the intron 1 variant in FTO, the significant effect of the SNP on BMI and obesity risk being restricted to subjects with no university education [86].

Age-dependent genetic associations have been described both in the context of monogenic and polygenic obesity. An age-dependent penetrance of MC4R pathogenic and monogenic mutations on obesity has been found in multigenerational pedigrees, the effect of mutations on the obesity phenotype being amplified by the development of an "obesogenic" environment [2]. The longitudinal study of adult MC4R mutation carriers showed an increasing age-dependent penetrance (37% at 20 years versus 60% at >40 years) [2]. The life-course analysis of the intronic FTO gene variant and body mass index in independent longitudinal studies indicates that most of the effect of the SNP on BMI gain occurs during childhood, adolescence and young adulthood [87-89].

Gender can be assimilated as a specific environmental condition. Females are at higher risk of developing morbid obesity than males [90]. These discrepancies could be explained in part by female-specific genetic associations or by stronger effect sizes of genetic variants in females. This was observed for the carriers of MC4R pathogenic monogenic mutations since BMI was about twice as strong in females than in males [2, 91]. The effect of the functional polymorphism R125W polymorphism in TBC1 domain family member 1 (TBC1D1) gene on severe obesity risk was restricted to females in French and US populations [92, 93]. Seven out of 14 loci convincingly associated with waist to hip ratio exhibited marked sexual dimorphism, all with a stronger effect on the phenotype in women than men [94, 95].

Ethnicity can be considered as an environmental factor that affects the genetic susceptibility to obesity. A convincing example of ethnic-specific association with obesity has been reported for the SIM1 gene. Variants in intronic regions of SIM1 were strongly associated with BMI and obesity risk (P = 4 x 10-7) in Pima Indians contrarily to French Europeans for which a major contribution of SIM1 common variants in polygenic obesity susceptibility was excluded [96, 97]. A functional coding variant (W64R) [98] in the ADRB3 gene has also been convincingly associated with BMI in East Asian but not in European subjects in a large meta-analysis of 44,833 subjects [69], the effect of the R64 allele on BMI increase being four-fold higher in Asian than in European subjects. More recently, a SNP (rs2074356) in the 24th intron of the C12orf51 transcript has been strongly associated with waist to hip ratio (P = 7.8 x 10-12) in the Korean population [99]. This variant has not been identified in a large GWAS meta-analysis for waist to hip ratio conducted in 77,167 individuals of European ancestry [95], suggesting an ethnic-specific association at this locus. These studies highlight the complex interplay between genetic susceptibility to obesity and environment.

Genes Influencing Response to Treatment

To date, three main therapeutic options are proposed to treat obesity: lifestyle intervention, pharmacotherapy and bariatric surgery. The aim of these therapeutics for obesity are to lose weight and maintain this weight-loss on the long term and attenuate co-morbidities related to obesity. There is growing evidence that genetic factors not only predispose to weight gain and development of obesity, but also modulate the response to therapeutic intervention in terms of weight loss.

Lifestyle Modifications

Individuals with MC4R or POMC monogenic conditions respond well to hypocaloric dietary or multidisciplinary (exercise, behavior, nutrition therapy) interventions as do non-monogenic obese subjects [100, 101] but MC4R individuals fail to maintain weight loss after intervention [101]. The major gene variant contributing to polygenic obesity FTO does not modify the response to lifestyle intervention in terms of weight loss [102], but may interact with specific components of the lifestyle intervention program like the type of diet proposed during the caloric restriction program (high-fat, low-fat, Mediterranean diets) [103, 104] or with physical activity [105] to modulate weight loss.

Pharmacotherapy

To date, only one successful personalized medicine approach which is based on a genetic diagnosis has been reported in the literature in the context of obesity: individuals with congenital leptin deficiency can be treated with daily injections of recombinant human leptin, which reverses the obesity and associated phenotypic abnormalities [106]. Leptin administration dramatically reduces food intake, fat mass, hyperinsulinemia, and hyperlipidemia, restores normal pubertal development, endocrine and immune function and increases performances in many neurocognitive domains [107]. Individuals with complete leptin deficiency are extremely rare (14 are reported so far worldwide) but peripheral leptin supplementation may also be extended to a numerically significant group of obese subjects with partial leptin deficiency, on the observation that peripheral leptin supplementation induces significant weight loss in those with low levels of leptin [108]. In addition, chemical chaperones and pharmacological agonists efficiently restore cell surface expression and endogenous agonist response of mutated melanocortin 4 receptors [109, 110], but in vivo beneficial effects in MC4R deficient monogenic patients remain to be demonstrated.

To date, the two main anti-obesity drugs used are orlistat and sibutramine (a saturated derivative of lipstatin and a serotonin-norepinephrine reuptake inhibitor, respectively). The guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene C825T polymorphism is highly predictive for the identification of obese individuals who will benefit from sibutramine treatment. Thus, three independent pharmacogenetic studies have shown an association between the GNB3 C825T polymorphism and weight loss induced by sibutramine [111-113]. Interestingly, this locus has not been identified by recent GWAS on obesity-related traits, suggesting that the genes associated with BMI variation and obesity risk may be at least partly different from genes involved in therapeutic response in terms of weight loss.

Bariatric Surgery

Bariatric surgery is the most effective long-term treatment for severe obesity, reducing obesity-associated co-morbidities but the mechanisms of weight loss after bariatric surgery and the role of central energy homeostatic pathways in this weight loss process are not well understood. Two recent studies assessed the response to bariatric surgery of MC4R monogenic mutation carriers [114, 115]. The Rouxen-Y gastric bypass surgery was associated with a similar percentage of excess weight loss in four heterozygous MC4R mutation carriers and in matched MC4R mutation non-carrier obese controls [115]. On the contrary, an adolescent with complete MC4R deficiency underwent laparoscopic adjustable gastric banding at 18 years of age which resulted in an initial, but not long-term weight loss [114]. These preliminary results need to be confirmed in larger studies, but logically suggest that diversionary operations, which are more invasive, efficiently improve the neuro-hormonal control of satiety better than gastric banding procedures, and are therefore indicated in monogenic hyperphagic subjects.

In the Swedish obesity intervention study, the FTO obesity predisposing allele carriers lost 3kg less than common allele homozygotes after obesity surgery, and this association was restricted to those undergoing banding surgery but was not significant in the gastric bypass operated subjects [116]. In a cohort of 1,001 severely obese subjects who underwent gastric bypass surgery, an allelic risk score combining the genetic information of four obesity-associated SNPs was significantly associated with postoperative weight loss trajectories [117]. Thus, obesity predisposing genes modulate the response to therapeutic options in terms of weight loss suggesting that genetic diagnosis combined with a genomic personalized medicine approach is a plausible strategy in order to design and implement the most suitable treatment and to achieve higher rates of therapeutic success.

Obesity Genes and Disease Prediction

Traditional approaches for the management of overweight and obesity have proven poor long term efficacy and obesity surgery is an efficient but invasive procedure. Prevention may therefore be considered as a promising strategy to face the obesity epidemic. In that context, the use of genetic information in clinical practice to predict individuals at high risk early in life and before the development of the disease remains the 'Holy Grail' for many geneticists [118]. Is the current knowledge about obesity genetics, sufficient to envisage such translational medicine applications?

Common Genetic Variants: Still Few Informative

GWAS allowed the identification of 36 polymorphisms robustly associated with BMI. However, identified variants have small effect sizes and collectively explain 1.45% of the variance in BMI (0.34% explained by the SNP in intron 1 of FTO alone) [12]. Therefore, it is not surprising that the combined information of 12-20 obesity predisposing SNPs provides only a slight increase in the ability to predict obesity in comparison with conventional nongenetic risk factors and has no clinical utility [119]. Risk prediction using GWAS remain conceivable despite the fact that individual effect sizes of variants associated with the phenotype are mostly small. In fact, it seems that many disease-associated variants are not yet identified prospects for risk prediction, but may improve if more disease predisposing variants are included in the models [120]. New iterative algorithms have been recently proposed to make better use of the whole-genome SNP information to improve the performance of disease risk assessment by utilizing a larger number of SNPs than those which reach genome-wide significance [120, 121].

Monogenic Genes may Explain a Non-Negligible Fraction of Obesity

The cumulative prevalence of monogenic obesity elucidated by the eight currently known genes and the 16p11.2 deletion has not been evaluated in a randomly ascertained cohort of obese subjects to date, but may be estimated between 5 and 10 %. These results re-emphasize the importance of monogenic obesity in elucidating the heritability of obesity, and Mendelian forms of obesity may provide a non-negligible predictive value in classifying young subjects at high risk for the development of childhood obesity, as deleterious coding mutations or chromosomal aberrations in these genes / regions induce highly penetrant forms of obesity. subjects carrying these mutations, present specific features according to the impaired gene (such as a low level of circulating leptin despite severe obesity, a susceptibility to infections, intestinal dysfunction, reactive hypoglycaemia, red hair and pale skin, adrenal insufficiency) that can guide gene sequencing approaches. Early diagnosis is fundamental for personalized prevention and effective therapeutic management, and in young non-obese individuals carrying MC4R monogenic mutations, an appropriate medical follow-up to prevent or at least delay the onset of obesity [122].

As hyperphagia is a common feature of monogenic obesity, the most effective preventive strategy may be stringent restriction of food access. This will require training and active participation of the parents and care providers and the identification of critical environmental components (physical activity, rural / urban environment, dietary profile, family structure, socioeconomic status, social network, psychosocial stress) that modulate the penetrance of obesity associated with pathogenic mutations in order to avoid unhealthy environments for these subjects.

In conclusion, we have demonstrated that 15 years of gene identification efforts have considerably modified our understanding of the biology of obesity. Promising approaches such as whole-exome and ultimately whole-genome sequencing have the potential to lead to an exhaustive map of obesity predisposing genes in the near future. Recent gene identification efforts have provided a more comprehensive picture of the biological mechanisms involved in the development of obesity and we feel that this information can be meaningful not only for scientists and clinicians but for a more general audience. For instance, the recent discoveries in genetics have found that people differ in their perceptions of hunger and satiety on a genetic basis and that predisposed subgroups of the population may be particularly vulnerable to obesity in “obesogenic” societies with unlimited access to food. This notion must lead to a more open attitude toward obese people and a reduction in discrimination against them [123], it is clear that obesity cannot be considered as a consequence only of indolence or lack of will, as often thought in our societies. In the long term, we are confident that progress in genetics will help to develop useful diagnostic and predictive tests and design new treatments.

ACKNOWLEDGEMENTS

We thank Yoan Gerrard for the editing of the manuscript, and the reviewers for their helpful comments.

AUTHORS’ CONTRIBUTIONS

Both authors contributed to the conception and production of the manuscript and approved the final version.

REFERENCES

  • 1.Hirschhorn JN. Genome wide association studies -- Illuminating biologic pathways. N. Engl. J. Med. 2009;360(17):1699–1701. doi: 10.1056/NEJMp0808934. [DOI] [PubMed] [Google Scholar]
  • 2.Stutzmann F, Tan K, Vatin V, Dina C, Jouret B, Tichet J, Balkau B, Potoczna N, Horber F, O'Rahilly S, Farooqi IS, Froguel P, Meyre D. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes. 2008;57(9):2511–2518. doi: 10.2337/db08-0153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Geller F, Reichwald K, Dempfle A, Illig T, Vollmert C, Herpertz S, Siffert W, Platzer M, Hess C, Gudermann T, Biebermann H, Wichmann HE, Schafer H, Hinney A, Hebebrand J. Melanocortin-4 receptor gene variant I103 is negatively associated with obesity. Am. J. Hum. Genet. 2004;74(3):572–581. doi: 10.1086/382490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Stutzmann F, Vatin V, Cauchi S, Morandi A, Jouret B, Landt O, Tounian P, Levy-Marchal C, Buzzetti R, Pinelli L, Balkau B, Horber F, Bougneres P, Froguel P, Meyre D. Non-synonymous polymorphisms in melanocortin-4 receptor protect against obesity: the two facets of a Janus obesity gene. Hum. Mol. Genet. 2007;16(15 ):1837–1844. doi: 10.1093/hmg/ddm132. [DOI] [PubMed] [Google Scholar]
  • 5.Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, Inouye M, Freathy RM, Attwood AP, Beckmann JS, Berndt SI, Jacobs KB, Chanock SJ, Hayes RB, Bergmann S, Bennett AJ, Bingham SA, Bochud M, Brown M, Cauchi S, Connell JM, Cooper C, Smith GD, Day I, Dina C, De S, Dermitzakis ET, Doney AS, Elliott KS, Elliott P, Evans DM, Sadaf Farooqi I, Froguel P, Ghori J, Groves CJ, Gwilliam R, Hadley D, Hall AS, Hattersley AT, Hebebrand J, Heid IM, Lamina C, Gieger C, Illig T, Meitinger T, Wichmann HE, Herrera B, Hinney A, Hunt SE, Jarvelin MR, Johnson T, Jolley JD, Karpe F, Keniry A, Khaw KT, Luben RN, Mangino M, Marchini J, McArdle WL, McGinnis R, Meyre D, Munroe PB, Morris AD, Ness AR, Neville MJ, Nica AC, Ong KK, O'Rahilly S, Owen KR, Palmer CN, Papadakis K, Potter S, Pouta A, Qi L, Randall JC, Rayner NW, Ring SM, Sandhu MS, Scherag A, Sims MA, Song K, Soranzo N, Speliotes EK, Syddall HE, Teichmann SA, Timpson NJ, Tobias JH, Uda M, Vogel CI, Wallace C, Waterworth DM, Weedon MN, Willer CJ, Wraight; Yuan X, Zeggini E, Hirschhorn JN, Strachan DP, Ouwehand WH, Caulfield MJ, Samani NJ, Frayling TM, Vollenweider P, Waeber G, Mooser V, Deloukas P, McCarthy MI, Wareham NJ, Barroso I, Jacobs KB, Chanock SJ, Hayes RB, Lamina C, Gieger C, Illig T, Meitinger T, Wichmann HE, Kraft P, Hankinson SE, Hunter DJ, Hu FB, Lyon HN, Voight BF, Ridderstrale M, Groop L, Scheet P, Sanna S, Abecasis GR, Albai G, Nagaraja R, Schlessinger D, Jackson AU, Tuomilehto J, Collins FS, Boehnke M, Mohlke KL. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat. Genet. 2008;40(6):768–775. doi: 10.1038/ng.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol. 2010;8(1):e1000294. doi: 10.1371/journal.pbio.1000294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Scherag A, Jarick I, Grothe J, Biebermann H, Scherag S, Volckmar AL, Vogel CI, Greene B, Hebebrand J, Hinney A. Investigation of a genome wide association signal for obesity: synthetic association and haplotype analyses at the melanocortin 4 receptor gene locus. PLoS One. 2010;5(11):e13967. doi: 10.1371/journal.pone.0013967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A, Styrkarsdottir U, Gretarsdottir S, Thorlacius S, Jonsdottir I, Jonsdottir T, Olafsdottir EJ, Olafsdottir GH, Jonsson T, Jonsson F, Borch-Johnsen K, Hansen T, Andersen G, Jorgensen T, Lauritzen T, Aben KK, Verbeek AL, Roeleveld N, Kampman E, Yanek LR, Becker LC, Tryggvadottir L, Rafnar T, Becker DM, Gulcher J, Kiemeney LA, Pedersen O, Kong A, Thorsteinsdottir U, Stefansson K. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat. Genet. 2009;41(1):18–24. doi: 10.1038/ng.274. [DOI] [PubMed] [Google Scholar]
  • 9.Bochukova EG, Huang N, Keogh J, Henning E, Purmann C, Blaszczyk K, Saeed S, Hamilton-Shield J, Clayton-Smith J, O'Rahilly S, Hurles ME, Farooqi IS. Large, rare chromosomal deletions associated with severe early-onset obesity. Nature. 2009;463(7281):666–670. doi: 10.1038/nature08689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Bachmann-Gagescu R, Mefford HC, Cowan C, Glew GM, Hing AV, Wallace S, Bader PI, Hamati A, Reitnauer PJ, Smith R, Stockton DW, Muhle H, Helbig I, Eichler EE, Ballif BC, Rosenfeld J, Tsuchiya KD. Recurrent 200-kb deletions of 16p11.2 that include the SH2B1 gene are associated with developmental delay and obesity. Genet. Med. 2010;12(10):641–647. doi: 10.1097/GIM.0b013e3181ef4286. [DOI] [PubMed] [Google Scholar]
  • 11.Ren D, Zhou Y, Morris D, Li M, Li Z, Rui L. Neuronal SH2B1 is essential for controlling energy and glucose homeostasis. J. Clin. Invest. 2007;117(2):397–406. doi: 10.1172/JCI29417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Allen HL, Lindgren CM, Luan J, Magi R, Randall JC, Vedantam S, Winkler TW, Qi L, Workalemahu T, Heid IM, Steinthorsdottir V, Stringham HM, Weedon MN, Wheeler E, Wood AR, Ferreira T, Weyant RJ, Segre AV, Estrada K, Liang L, Nemesh J, Park JH, Gustafsson S, Kilpelainen TO, Yang J, Bouatia-Naji N, Esko T, Feitosa MF, Kutalik Z, Mangino M, Raychaudhuri S, Scherag A, Smith AV, Welch R, Zhao JH, Aben KK, Absher DM, Amin N, Dixon AL, Fisher E, Glazer NL, Goddard ME, Heard-Costa NL, Hoesel V, Hottenga JJ, Johansson A, Johnson T, Ketkar S, Lamina C, Li S, Moffatt MF, Myers RH, Narisu N, Perry JR, Peters MJ, Preuss M, Ripatti S, Rivadeneira F, Sandholt C, Scott LJ, Timpson NJ, Tyrer JP, van Wingerden S, Watanabe RM, White CC, Wiklund F, Barlassina C, Chasman DI, Cooper MN, Jansson JO, Lawrence RW, Pellikka N, Prokopenko I, Shi J, Thiering E, Alavere H, Alibrandi MT, Almgren P, Arnold AM, Aspelund T, Atwood LD, Balkau B, Balmforth AJ, Bennett AJ, Ben-Shlomo Y, Bergman RN, Bergmann S, Biebermann H, Blakemore AI, Boes T, Bonnycastle LL, Bornstein SR, Brown MJ, Buchanan TA, Busonero F, Campbell H, Cappuccio FP, Cavalcanti-Proenca C, Chen YD, Chen CM, Chines PS, Clarke R, Coin L, Connell J, Day IN, Heijer M, Duan J, Ebrahim S, Elliott P, Elosua R, Eiriksdottir G, Erdos MR, Eriksson JG, Facheris MF, Felix SB, Fischer-Posovszky P, Folsom AR, Friedrich N, Freimer NB, Fu M, Gaget S, Gejman PV, Geus EJ, Gieger C, Gjesing AP, Goel A, Goyette P, Grallert H, Grassler J, Greenawalt DM, Groves CJ, Gudnason V, Guiducci C, Hartikainen AL, Hassanali N, Hall AS, Havulinna AS, Hayward C, Heath AC, Hengstenberg C, Hicks AA, Hinney A, Hofman A, Homuth G, Hui J, Igl W, Iribarren C, Isomaa B, Jacobs KB, Jarick I, Jewell E, John U, Jorgensen T, Jousilahti P, Jula A, Kaakinen M, Kajantie E, Kaplan LM, Kathiresan S, Kettunen J, Kinnunen L, Knowles JW, Kolcic I, Konig IR, Koskinen S, Kovacs P, Kuusisto J, Kraft P, Kvaloy K, Laitinen J, Lantieri O, Lanzani C, Launer LJ, Lecoeur C, Lehtimaki T, Lettre G, Liu J, Lokki ML, Lorentzon M, Luben RN, Ludwig B, Manunta P, Marek D, Marre M, Martin NG, McArdle WL, McCarthy A, McKnight B, Meitinger T, Melander O, Meyre D, Midthjell K, Montgomery GW, Morken MA, Morris AP, Mulic R, Ngwa JS, Nelis M, Neville MJ, Nyholt DR, O'Donnell CJ, O'Rahilly S, Ong KK, Oostra B, Pare G, Parker AN, Perola M, Pichler I, Pietilainen KH, Platou CG, Polasek O, Pouta A, Rafelt S, Raitakari O, Rayner NW, Ridderstrale M, Rief W, Ruokonen A, Robertson NR, Rzehak P, Salomaa V, Sanders AR, Sandhu MS, Sanna S, Saramies J, Savolainen MJ, Scherag S, Schipf S, Schreiber S, Schunkert H, Silander K, Sinisalo J, Siscovick DS, Smit JH, Soranzo N, Sovio U, Stephens J, Surakka I, Swift AJ, Tammesoo ML, Tardif JC, Teder-Laving M, Teslovich TM, Thompson JR, Thomson B, Tonjes A, Tuomi T, van Meurs JB, van Ommen GJ, Vatin V, Viikari J, Visvikis-Siest S, Vitart V, Vogel CI, Voight BF, Waite LL, Wallaschofski H, Walters GB, Widen E, Wiegand S, Wild SH, Willemsen G, Witte DR, Witteman JC, Xu J, Zhang Q, Zgaga L, Ziegler A, Zitting P, Beilby JP, Farooqi IS, Hebebrand J, Huikuri HV, James AL, Kahonen M, Levinson DF, Macciardi F, Nieminen MS, Ohlsson C, Palmer LJ, Ridker PM, Stumvoll M, Beckmann JS, Boeing H, Boerwinkle E, Boomsma DI, Caulfield MJ, Chanock SJ, Collins FS, Cupples LA, Smith GD, Erdmann J, Froguel P, Gronberg H, Gyllensten U, Hall P, Hansen T, Harris TB, Hattersley AT, Hayes RB, Heinrich J, Hu FB, Hveem K, Illig T, Jarvelin MR, Kaprio J, Karpe F, Khaw KT, Kiemeney LA, Krude H, Laakso M, Lawlor DA, Metspalu A, Munroe PB, Ouwehand WH, Pedersen O, Penninx BW, Peters A, Pramstaller PP, Quertermous T, Reinehr T, Rissanen A, Rudan I, Samani NJ, Schwarz PE, Shuldiner AR, Spector TD, Tuomilehto J, Uda M, Uitterlinden A, Valle TT, Wabitsch M, Waeber G, Wareham NJ, Watkins H, Wilson JF, Wright AF, Zillikens MC, Chatterjee N, McCarroll SA, Purcell S, Schadt EE, Visscher PM, Assimes TL, Borecki IB, Deloukas P, Fox CS, Groop LC, Haritunians T, Hunter DJ, Kaplan RC, Mohlke KL, O'Connell JR, Peltonen L, Schlessinger D, Strachan DP, van Duijn CM, Wichmann HE, Frayling TM, Thorsteinsdottir U, Abecasis GR, Barroso I, Boehnke M, Stefansson K, North KE, McCarthy MI, Hirschhorn JN, Ingelsson E, Loos RJ. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 2010;42(11):937–948. doi: 10.1038/ng.686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Church C, Lee S, Bagg EA, McTaggart JS, Deacon R, Gerken T, Lee A, Moir L, Mecinovic J, Quwailid MM, Schofield CJ, Ashcroft FM, Cox RD. A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene. PLoS Genet. 2009;5(8):e1000599. doi: 10.1371/journal.pgen.1000599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Church C, Moir L, McMurray F, Girard C, Banks GT, Teboul L, Wells S, Bruning JC, Nolan PM, Ashcroft FM, Cox RD. Overexpression of Fto leads to increased food intake and results in obesity. Nat. Genet. 2010;42(12 ):1086–1092. doi: 10.1038/ng.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Meyre D, Proulx K, Kawagoe-Takaki H, Vatin V, Gutierrez-Aguilar R, Lyon D, Ma M, Choquet H, Horber F, Van Hul W, Van Gaal L, Balkau B, Visvikis-Siest S, Pattou F, Farooqi IS, Saudek V, O'Rahilly S, Froguel P, Sedgwick B, Yeo GS. Prevalence of loss of function FTO mutations in lean and obese individuals. Diabetes. 2010;59(1):311–318. doi: 10.2337/db09-0703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.O'Rahilly S, Farooqi IS. Human obesity as a heritable disorder of the central control of energy balance. Int. J. Obes. (Lond) 2008;32(Suppl 7):S55–61. doi: 10.1038/ijo.2008.239. [DOI] [PubMed] [Google Scholar]
  • 17.Walley AJ, Asher JE, Froguel P. The genetic contribution to non-syndromic human obesity. Nat. Rev. Genet. 2009;10(7):431–442. doi: 10.1038/nrg2594. [DOI] [PubMed] [Google Scholar]
  • 18.Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJ, Barroso I, Wareham NJ, Karpe F, Owen KR, Cardon LR, Walker M, Hitman GA, Palmer CN, Doney AS, Morris AD, Smith GD, Hattersley AT, McCarthy MI. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–894. doi: 10.1126/science.1141634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, Carlsson LM, Kiess W, Vatin V, Lecoeur C, Delplanque J, Vaillant E, Pattou F, Ruiz J, Weill J, Levy-Marchal C, Horber F, Potoczna N, Hercberg S, Le Stunff C, Bougneres P, Kovacs P, Marre M, Balkau B, Cauchi S, Chevre JC, Froguel P. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat. Genet. 2007;39(6):724–726. doi: 10.1038/ng2048. [DOI] [PubMed] [Google Scholar]
  • 20.Cecil JE, Tavendale R, Watt P, Hetherington MM, Palmer CN. An obesity-associated FTO gene variant and increased energy intake in children. N. Engl. J. Med. 2008;359(24):2558–2566. doi: 10.1056/NEJMoa0803839. [DOI] [PubMed] [Google Scholar]
  • 21.Timpson NJ, Emmett PM, Frayling TM, Rogers I, Hattersley AT, McCarthy MI, Davey Smith G. The fat mass- and obesity-associated locus and dietary intake in children. Am. J. Clin. Nutr. 2008;88(4):971–978. doi: 10.1093/ajcn/88.4.971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Speakman JR, Rance KA, Johnstone AM. Polymorphisms of the FTO gene are associated with variation in energy intake, but not energy expenditure. Obesity (Silver Spring) 2008;16(8):1961–1965. doi: 10.1038/oby.2008.318. [DOI] [PubMed] [Google Scholar]
  • 23.Wardle J, Carnell S, Haworth CM, Farooqi IS, O'Rahilly S, Plomin R. Obesity associated genetic variation in FTO is associated with diminished satiety. J. Clin. Endocrinol. Metab. 2008;93(9):3640–3643. doi: 10.1210/jc.2008-0472. [DOI] [PubMed] [Google Scholar]
  • 24.den Hoed M, Westerterp-Plantenga MS, Bouwman FG, Mariman EC, Westerterp KR. Postprandial responses in hunger and satiety are associated with the rs9939609 single nucleotide polymorphism in FTO. Am. J. Clin. Nutr. 2009;90(5):1426–1432. doi: 10.3945/ajcn.2009.28053. [DOI] [PubMed] [Google Scholar]
  • 25.Stutzmann F, Cauchi S, Durand E, Calvacanti-Proenca C, Pigeyre M, Hartikainen AL, Sovio U, Tichet J, Marre M, Weill J, Balkau B, Potoczna N, Laitinen J, Elliott P, Jarvelin MR, Horber F, Meyre D, Froguel P. Common genetic variation near MC4R is associated with eating behaviour patterns in European populations. Int. J. Obes. (Lond) 2009;33(3):373–378. doi: 10.1038/ijo.2008.279. [DOI] [PubMed] [Google Scholar]
  • 26.Valladares M, Dominguez-Vasquez P, Obregon AM, Weisstaub G, Burrows R, Maiz A, Santos JL. Melanocortin-4 receptor gene variants in Chilean families: association with childhood obesity and eating behavior. Nutr. Neurosci. 2010;13(2):71–78. doi: 10.1179/147683010X12611460763643. [DOI] [PubMed] [Google Scholar]
  • 27.Qi L, Kraft P, Hunter DJ, Hu FB. The common obesity variant near MC4R gene is associated with higher intakes of total energy and dietary fat, weight change and diabetes risk in women. Hum. Mol. Genet. 2008;17(22):3502–3508. doi: 10.1093/hmg/ddn242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Bauer F, Elbers CC, Adan RA, Loos RJ, Onland-Moret NC, Grobbee DE, van Vliet-Ostaptchouk JV, Wijmenga C, van der Schouw YT. Obesity genes identified in genome-wide association studies are associated with adiposity measures and potentially with nutrient-specific food preference. Am. J. Clin. Nutr. 2009;90(4):951–959. doi: 10.3945/ajcn.2009.27781. [DOI] [PubMed] [Google Scholar]
  • 29.Wardle J, Carnell S. Appetite is a heritable phenotype associated with adiposity. Ann. Behav. Med. 2009 doi: 10.1007/s12160-009-9116-5. (Epub ahed of print) [DOI] [PubMed] [Google Scholar]
  • 30.Fricker J, Fumeron F, Clair D, Apfelbaum M. A positive correlation between energy intake and body mass index in a population of 1312 overweight subjects. Int. J. Obes. 1989;13(5):673–681. [PubMed] [Google Scholar]
  • 31.Peters T, Ausmeier K, Ruther U. Cloning of Fatso (Fto), a novel gene deleted by the Fused toes (Ft) mouse mutation. Mamm. Genome. 1999;10(10):983–986. doi: 10.1007/s003359901144. [DOI] [PubMed] [Google Scholar]
  • 32.Wing MR, Ziegler J, Langefeld CD, Ng MC, Haffner SM, Norris JM, Goodarzi MO, Bowden DW. Analysis of FTO gene variants with measures of obesity and glucose homeostasis in the IRAS Family Study. Hum. Genet. 2009;125(5-6):615–626. doi: 10.1007/s00439-009-0656-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Hotta K, Nakata Y, Matsuo T, Kamohara S, Kotani K, Komatsu R, Itoh N, Mineo I, Wada J, Masuzaki H, Yoneda M, Nakajima A, Miyazaki S, Tokunaga K, Kawamoto M, Funahashi T, Hamaguchi K, Yamada K, Hanafusa T, Oikawa S, Yoshimatsu H, Nakao K, Sakata T, Matsuzawa Y, Tanaka K, Kamatani N, Nakamura Y. Variations in the FTO gene are associated with severe obesity in the Japanese. J. Hum. Genet. 2008;53(6):546–553. doi: 10.1007/s10038-008-0283-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Rees SD, Islam M, Hydrie MZ, Chaudhary B, Bellary S, Hashmi S, O'Hare JP, Kumar S, Sanghera DK, Chaturvedi N, Barnett AH, Shera AS, Weedon MN, Basit A, Frayling TM, Kelly MA, Jafar TH. An FTO variant is associated with Type 2 diabetes in South Asian populations after accounting for body mass index and waist circumference. Diabet. Med. 2011 doi: 10.1111/j.1464-5491.2011.03257.x. (Epub ahed of print). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Villalobos-Comparan M, Teresa Flores-Dorantes M, Teresa Villarreal-Molina M, Rodriguez-Cruz M, Garcia-Ulloa AC, Robles L, Huertas-Vazquez A, Saucedo-Villarreal N, Lopez-Alarcon M, Sanchez-Munoz F, Dominguez-Lopez A, Gutierrez-Aguilar R, Menjivar M, Coral-Vazquez R, Hernandez-Stengele G, Vital-Reyes VS, Acuna-Alonzo V, Romero-Hidalgo S, Ruiz-Gomez DG, Riano-Barros D, Herrera MF, Gomez-Perez FJ, Froguel P, Garcia-Garcia E, Teresa Tusie-Luna M, Aguilar-Salinas CA, Canizales-Quinteros S. The FTO gene is associated with adulthood obesity in the Mexican population. Obesity (Silver Spring) 2008;16(10):2296–2301. doi: 10.1038/oby.2008.367. [DOI] [PubMed] [Google Scholar]
  • 36.Rong R, Hanson RL, Ortiz D, Wiedrich C, Kobes S, Knowler WC, Bogardus C, Baier LJ. Association analysis of variation in/near FTO, CDKAL1, SLC30A8, HHEX, EXT2, IGF2BP2, LOC387761, and CDKN2B with type 2 diabetes and related quantitative traits in Pima Indians. Diabetes. 2009;58(2):478–488. doi: 10.2337/db08-0877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Boissel S, Reish O, Proulx K, Kawagoe-Takaki H, Sedgwick B, Yeo GS, Meyre D, Golzio C, Molinari F, Kadhom N, Etchevers HC, Saudek V, Farooqi IS, Froguel P, Lindahl T, O'Rahilly S, Munnich A, Colleaux L. Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations. Am. J. Hum. Genet. 2009;85(1):106–111. doi: 10.1016/j.ajhg.2009.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Fischer J, Koch L, Emmerling C, Vierkotten J, Peters T, Bruning JC, Ruther U. Inactivation of the Fto gene protects from obesity. Nature. 2009;458(7240):894–898. doi: 10.1038/nature07848. [DOI] [PubMed] [Google Scholar]
  • 39.Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, Hewitson KS, Yeo GS, McDonough MA, Cunliffe S, McNeill LA, Galvanovskis J, Rorsman P, Robins P, Prieur X, Coll AP, Ma M, Jovanovic Z, Farooqi IS, Sedgwick B, Barroso I, Lindahl T, Ponting CP, Ashcroft FM, O'Rahilly S, Schofield CJ. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318(5855):1469–1472. doi: 10.1126/science.1151710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Tung YC, Ayuso E, Shan X, Bosch F, O'Rahilly S, Coll AP, Yeo GS. Hypothalamic-specific manipulation of Fto, the ortholog of the human obesity gene FTO, affects food intake in rats. PLoS One. 2010;5(1):e8771. doi: 10.1371/journal.pone.0008771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Wang P, Yang FJ, Du H, Guan YF, Xu TY, Xu XW, Su DF, Miao CY. Involvement of leptin receptor (LepRb)-STAT3 signaling pathway in brain FTO downregulation during energy restriction. Mol. Med. 2011 doi: 10.2119/molmed.2010.00134. [Epub ahead of print]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Han Z, Niu T, Chang J, Lei X, Zhao M, Wang Q, Cheng W, Wang J, Feng Y, Chai J. Crystal structure of the FTO protein reveals basis for its substrate specificity. Nature. 2010;464(7292):1205–1209. doi: 10.1038/nature08921. [DOI] [PubMed] [Google Scholar]
  • 43.Wu Q, Saunders RA, Szkudlarek-Mikho M, Serna Ide L, Chin KV. The obesity-associated Fto gene is a transcriptional coactivator. Biochem. Biophys. Res. Commun. 2010;401(3):390–395. doi: 10.1016/j.bbrc.2010.09.064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Bell CG, Finer S, Lindgren CM, Wilson GA, Rakyan VK, Teschendorff AE, Akan P, Stupka E, Down TA, Prokopenko I, Morison IM, Mill J, Pidsley R, Deloukas P, Frayling TM, Hattersley AT, McCarthy MI, Beck S, Hitman GA. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. PLoS One. 2010;5(11):e14040. doi: 10.1371/journal.pone.0014040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 2003;32(1):1–22. doi: 10.1093/ije/dyg070. [DOI] [PubMed] [Google Scholar]
  • 46.Li S, Zhao JH, Luan J, Langenberg C, Luben RN, Khaw KT, Wareham NJ, Loos RJ. Genetic predisposition to obesity leads to increased risk of type 2 diabetes. Diabetologia. 2011;54(4):776–782. doi: 10.1007/s00125-011-2044-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Freathy RM, Timpson NJ, Lawlor DA, Pouta A, Ben-Shlomo Y, Ruokonen A, Ebrahim S, Shields B, Zeggini E, Weedon MN, Lindgren CM, Lango H, Melzer D, Ferrucci L, Paolisso G, Neville MJ, Karpe F, Palmer CN, Morris AD, Elliott P, Jarvelin MR, Smith GD, McCarthy MI, Hattersley AT, Frayling TM. Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. Diabetes. 2008;57(5):1419–1426. doi: 10.2337/db07-1466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Do R, Bailey SD, Desbiens K, Belisle A, Montpetit A, Bouchard C, Perusse L, Vohl MC, Engert JC. Genetic variants of FTO influence adiposity, insulin sensitivity, leptin levels, and resting metabolic rate in the Quebec Family Study. Diabetes. 2008;57(4):1147–1150. doi: 10.2337/db07-1267. [DOI] [PubMed] [Google Scholar]
  • 49.Timpson NJ, Harbord R, Davey Smith G, Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. Does greater adiposity increase blood pressure and hypertension risk?: Mendelian randomization using the FTO/MC4R genotype. Hypertension. 2009;54(1):84–90. doi: 10.1161/HYPERTENSIONAHA.109.130005. [DOI] [PubMed] [Google Scholar]
  • 50.Welsh P, Polisecki E, Robertson M, Jahn S, Buckley BM, de Craen AJ, Ford I, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Hingorani AD, Smith GD, Schaefer E, Sattar N. Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach. J. Clin. Endocrinol. Metab. 2010;95(1):93–99. doi: 10.1210/jc.2009-1064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Timpson NJ, Sayers A, Davey-Smith G, Tobias JH. How does body fat influence bone mass in childhood? A Mendelian randomization approach. J. Bone Miner. Res. 2009;24(3):522–533. doi: 10.1359/jbmr.081109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Kivimaki M, Smith GD, Timpson NJ, Lawlor DA, Batty GD, Kahonen M, Juonala M, Ronnemaa T, Viikari JS, Lehtimaki T, Raitakari OT. Lifetime body mass index and later atherosclerosis risk in young adults: examining causal links using Mendelian randomization in the Cardiovascular Risk in Young Finns study. Eur. Heart J. 2008;29(20 ):2552–2560. doi: 10.1093/eurheartj/ehn252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Ahmad T, Chasman DI, Mora S, Pare G, Cook NR, Buring JE, Ridker PM, Lee IM. The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. Am. Heart J. 2010;160(6):1163–1169. doi: 10.1016/j.ahj.2010.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Brennan P, McKay J, Moore L, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chow WH, Rothman N, Chabrier A, Gaborieau V, Timpson N, Hung RJ, Smith GD. Obesity and cancer: Mendelian randomization approach utilizing the FTO genotype. Int. J. Epidemiol. 2009;38(4):971–975. doi: 10.1093/ije/dyp162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Lurie G, Gaudet MM, Spurdle AB, Carney ME, Wilkens LR, Yang HP, Weiss NS, Webb PM, Thompson PJ, Terada K, Setiawan VW, Rebbeck TR, Prescott J, Orlow I, O'Mara T, Olson SH, Narod SA, Matsuno RK, Lissowska J, Liang X, Levine DA, Le Marchand L, Kolonel LN, Henderson BE, Garcia-Closas M, Doherty JA, De Vivo I, Chen C, Brinton LA, Akbari MR, Goodman MT. The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-hispanic white women. PLoS One. 2010;6(2):e16756. doi: 10.1371/journal.pone.0016756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Lewis SJ, Murad A, Chen L, Davey Smith G, Donovan J, Palmer T, Hamdy F, Neal D, Lane JA, Davis M, Cox A, Martin RM. Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One. 2010;5(10):e13485. doi: 10.1371/journal.pone.0013485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Sabeti PC, Varilly P, Fry B, Lohmueller J, Hostetter E, Cotsapas C, Xie X, Byrne EH, McCarroll SA, Gaudet R, Schaffner SF, Lander ES, Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang W, Yu J, Zhang B, Zhang Q, Zhao H, Zhao H, Zhou J, Gabriel SB, Barry R, Blumenstiel B, Camargo A, Defelice M, Faggart M, Goyette M, Gupta S, Moore J, Nguyen H, Onofrio RC, Parkin M, Roy J, Stahl E, Winchester E, Ziaugra L, Altshuler D, Shen Y, Yao Z, Huang W, Chu X, He Y, Jin L, Liu Y, Shen Y, Sun W, Wang H, Wang Y, Wang Y, Xiong X, Xu L, Waye MM, Tsui SK, Xue H, Wong JT, Galver LM, Fan JB, Gunderson K, Murray SS, Oliphant AR, Chee MS, Montpetit A, Chagnon F, Ferretti V, Leboeuf M, Olivier JF, Phillips MS, Roumy S, Sallee C, Verner A, Hudson TJ, Kwok PY, Cai D, Koboldt DC, Miller RD, Pawlikowska L, Taillon-Miller P, Xiao M, Tsui LC, Mak W, Song YQ, Tam PK, Nakamura Y, Kawaguchi T, Kitamoto T, Morizono T, Nagashima A, Ohnishi Y, Sekine A, Tanaka T, Tsunoda T, Deloukas P, Bird CP, Delgado M, Dermitzakis ET, Gwilliam R, Hunt S, Morrison J, Powell D, Stranger BE, Whittaker P, Bentley DR, Daly MJ, de Bakker PI, Barrett J, Chretien YR, Maller J, McCarroll S, Patterson N, Pe'er I, Price A, Purcell S, Richter DJ, Sabeti P, Saxena R, Schaffner SF, Sham PC, Varilly P, Altshuler D, Stein LD, Krishnan L, Smith AV, Tello-Ruiz MK, Thorisson GA, Chakravarti A, Chen PE, Cutler DJ, Kashuk CS, Lin S, Abecasis GR, Guan W, Li Y, Munro HM, Qin ZS, Thomas DJ, McVean G, Auton A, Bottolo L, Cardin N, Eyheramendy S, Freeman C, Marchini J, Myers S, Spencer C, Stephens M, Donnelly P, Cardon LR, Clarke G, Evans DM, Morris AP, Weir BS, Tsunoda T, Johnson TA, Mullikin JC, Sherry ST, Feolo M, Skol A, Zhang H, Zeng C, Zhao H, Matsuda I, Fukushima Y, Macer DR, Suda E, Rotimi CN, Adebamowo CA, Ajayi I, Aniagwu T, Marshall PA, Nkwodimmah C, Royal CD, Leppert MF, Dixon M, Peiffer A, Qiu R, Kent A, Kato K, Niikawa N, Adewole IF, Knoppers BM, Foster MW, Clayton EW, Watkin J, Gibbs RA, Belmont JW, Muzny D, Nazareth L, Sodergren E, Weinstock GM, Wheeler DA, Yakub I, Gabriel SB, Onofrio RC, Richter DJ, Ziaugra L, Birren BW, Daly MJ, Altshuler D, Wilson RK, Fulton LL, Rogers J, Burton J, Carter NP, Clee CM, Griffiths M, Jones MC, McLay K, Plumb RW, Ross MT, Sims SK, Willey DL, Chen Z, Han H, Kang L, Godbout M, Wallenburg JC, L'Archeveque P, Bellemare G, Saeki K, Wang H, An D, Fu H, Li Q, Wang Z, Wang R, Holden AL, Brooks LD, McEwen JE, Guyer MS, Wang VO, Peterson JL, Shi M, Spiegel J, Sung LM, Zacharia LF, Collins FS, Kennedy K, Jamieson R, Stewart J. Genome-wide detection and characterization of positive selection in human populations. Nature. 2007;449(7164):913–918. doi: 10.1038/nature06250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Sabeti PC, Schaffner SF, Fry B, Lohmueller J, Varilly P, Shamovsky O, Palma A, Mikkelsen TS, Altshuler D, Lander ES. Positive natural selection in the human lineage. Science. 2006;312(5780):1614–1620. doi: 10.1126/science.1124309. [DOI] [PubMed] [Google Scholar]
  • 59. Wells JC. The evolution of human fatness and susceptibility to obesity: an ethological approach. Biol. Rev. Camb. Philos. Soc. 2006;81(2):183–205. doi: 10.1017/S1464793105006974. [DOI] [PubMed] [Google Scholar]
  • 60.Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am. J. Hum. Genet. 1962;14:353–362. [PMC free article] [PubMed] [Google Scholar]
  • 61.Enattah NS, Sahi T, Savilahti E, Terwilliger JD, Peltonen L, Jarvela I. Identification of a variant associated with adult-type hypolactasia. Nat. Genet. 2002;30(2):233–237. doi: 10.1038/ng826. [DOI] [PubMed] [Google Scholar]
  • 62.Rasinpera H, Kuokkanen M, Kolho KL, Lindahl H, Enattah NS, Savilahti E, Orpana A, Jarvela I. Transcriptional downregulation of the lactase (LCT) gene during childhood. Gut. 2005;54(11):1660–1661. doi: 10.1136/gut.2005.077404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Bersaglieri T, Sabeti PC, Patterson N, Vanderploeg T, Schaffner SF, Drake JA, Rhodes M, Reich DE, Hirschhorn JN. Genetic signatures of strong recent positive selection at the lactase gene. Am. J. Hum. Genet. 2004;74(6 ):1111–1120. doi: 10.1086/421051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Enattah NS, Jensen TG, Nielsen M, Lewinski R, Kuokkanen M, Rasinpera H, El-Shanti H, Seo JK, Alifrangis M, Khalil IF, Natah A, Ali A, Natah S, Comas D, Mehdi SQ, Groop L, Vestergaard EM, Imtiaz F, Rashed MS, Meyer B, Troelsen J, Peltonen L. Independent introduction of two lactase-persistence alleles into human populations reflects different history of adaptation to milk culture. Am. J. Hum. Genet. 2008;82(1):57–72. doi: 10.1016/j.ajhg.2007.09.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Smith GD, Lawlor DA, Timpson NJ, Baban J, Kiessling M, Day IN, Ebrahim S. Lactase persistence-related genetic variant: population substructure and health outcomes. Eur. J. Hum. Genet. 2009;17(3 ):357–367. doi: 10.1038/ejhg.2008.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Gugatschka M, Dobnig H, Fahrleitner-Pammer A, Pietschmann P, Kudlacek S, Strele A, Obermayer-Pietsch B. Molecularly-defined lactose malabsorption, milk consumption and anthropometric differences in adult males. Qjm. 2005;98(12):857–863. doi: 10.1093/qjmed/hci140. [DOI] [PubMed] [Google Scholar]
  • 67.Kettunen J, Silander K, Saarela O, Amin N, Muller M, Timpson N, Surakka I, Ripatti S, Laitinen J, Hartikainen AL, Pouta A, Lahermo P, Anttila V, Mannisto S, Jula A, Virtamo J, Salomaa V, Lehtimaki T, Raitakari O, Gieger C, Wichmann EH, Van Duijn CM, Smith GD, McCarthy MI, Jarvelin MR, Perola M, Peltonen L. European lactase persistence genotype shows evidence of association with increase in body mass index. Hum. Mol. Genet. 2010;19(6):1129–1136. doi: 10.1093/hmg/ddp561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Park KS, Shin HD, Park BL, Cheong HS, Cho YM, Lee HK, Lee JY, Lee JK, Oh B, Kimm K. Polymorphisms in the leptin receptor (LEPR)--putative association with obesity and T2DM. J. Hum. Genet. 2006;51(2):85–91. doi: 10.1007/s10038-005-0327-8. [DOI] [PubMed] [Google Scholar]
  • 69.Kurokawa N, Young EH, Oka Y, Satoh H, Wareham NJ, Sandhu MS, Loos RJ. The ADRB3 Trp64Arg variant and BMI: a meta-analysis of 44 833 individuals. Int. J. Obes. (Lond) 2008;32(8 ):1240–1249. doi: 10.1038/ijo.2008.90. [DOI] [PubMed] [Google Scholar]
  • 70.Grossman SR, Shylakhter I, Karlsson EK, Byrne EH, Morales S, Frieden G, Hostetter E, Angelino E, Garber M, Zuk O, Lander ES, Schaffner SF, Sabeti PC. A composite of multiple signals distinguishes causal variants in regions of positive selection. Science. 2010;327(5967):883–886. doi: 10.1126/science.1183863. [DOI] [PubMed] [Google Scholar]
  • 71.Cagliani R, Fumagalli M, Pozzoli U, Riva S, Comi GP, Torri F, Macciardi F, Bresolin N, Sironi M. Diverse evolutionary histories for beta-adrenoreceptor genes in humans. Am. J. Hum. Genet. 2009;85(1):64–75. doi: 10.1016/j.ajhg.2009.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, Waggoner SG, Tahl AR, Sklar P. Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol. Psychiatry. 2010;15(8):810–815. doi: 10.1038/mp.2009.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Southam L, Soranzo N, Montgomery SB, Frayling TM, McCarthy MI, Barroso I, Zeggini E. Is the thrifty genotype hypothesis supported by evidence based on confirmed type 2 diabetes- and obesity-susceptibility variants? Diabetologia. 2009;52(9):1846–1851. doi: 10.1007/s00125-009-1419-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Klimentidis YC, Abrams M, Wang J, Fernandez JR, Allison DB. Natural selection at genomic regions associated with obesity and type-2 diabetes: East Asians and sub-Saharan Africans exhibit high levels of differentiation at type-2 diabetes regions. Hum. Genet. 2011;129(4):407–418. doi: 10.1007/s00439-010-0935-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Schioth HB, Lagerstrom MC, Watanobe H, Jonsson L, Vergoni AV, Ringholm A, Skarphedinsson JO, Skuladottir GV, Klovins J, Fredriksson R. Functional role, structure, and evolution of the melanocortin-4 receptor. Ann. N. Y. Acad. Sci. 2003;994:74–83. doi: 10.1111/j.1749-6632.2003.tb03164.x. [DOI] [PubMed] [Google Scholar]
  • 76.Hughes DA, Hinney A, Brumm H, Wermter AK, Biebermann H, Hebebrand J, Stoneking M. Increased constraints on MC4R during primate and human evolution. Hum. Genet. 2009;124(6):633–647. doi: 10.1007/s00439-008-0591-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, Benca RM, Biggio J, Boggiano MM, Eisenmann JC, Elobeid M, Fontaine KR, Gluckman P, Hanlon EC, Katzmarzyk P, Pietrobelli A, Redden DT, Ruden DM, Wang C, Waterland RA, Wright SM, Allison DB. Ten putative contributors to the obesity epidemic. Crit. Rev. Food Sci. Nutr. 2009;49(10):868–913. doi: 10.1080/10408390903372599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Andreasen CH, Stender-Petersen KL, Mogensen MS, Torekov SS, Wegner L, Andersen G, Nielsen AL, Albrechtsen A, Borch-Johnsen K, Rasmussen SS, Clausen JO, Sandbaek A, Lauritzen T, Hansen L, Jorgensen T, Pedersen O, Hansen T. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes. 2008;57(1):95–101. doi: 10.2337/db07-0910. [DOI] [PubMed] [Google Scholar]
  • 79.Sonestedt E, Roos C, Gullberg B, Ericson U, Wirfalt E, Orho-Melander M. Fat and carbohydrate intake modify the association between genetic variation in the FTO genotype and obesity. Am. J. Clin. Nutr. 2009;90(5 ):1418–1425. doi: 10.3945/ajcn.2009.27958. [DOI] [PubMed] [Google Scholar]
  • 80.Sonestedt E, Gullberg B, Ericson U, Wirfalt E, Hedblad B, Orho-Melander M. Association between fat intake, physical activity and mortality depending on genetic variation in FTO. Int. J. Obes. (Lond) 2010 doi: 10.1038/ijo.2010.263. [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
  • 81.Ahmad T, Lee IM, Pare G, Chasman DI, Rose L, Ridker PM, Mora S. Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. women. Diabetes Care. 2011;34(3):675–680. doi: 10.2337/dc10-0948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Li S, Zhao JH, Luan J, Ekelund U, Luben RN, Khaw KT, Wareham NJ, Loos RJ. Physical activity attenuates the genetic predisposition to obesity in 20,000 men and women from EPIC-Norfolk prospective population study. PLoS Med. 2010;7(8):e1000332. doi: 10.1371/journal.pmed.1000332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Corella D, Peloso G, Arnett DK, Demissie S, Cupples LA, Tucker K, Lai CQ, Parnell LD, Coltell O, Lee YC, Ordovas JM. APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations. Arch. Intern. Med. 2009;169(20):1897–1906. doi: 10.1001/archinternmed.2009.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Corella D, Tai ES, Sorli JV, Chew SK, Coltell O, Sotos-Prieto M, Garcia-Rios A, Estruch R, Ordovas JM. Association between the APOA2 promoter polymorphism and body weight in Mediterranean and Asian populations: replication of a gene-saturated fat interaction. Int. J. Obes. (Lond) 2010 doi: 10.1038/ijo.2010.187. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Roskam AJ, Kunst AE, Van Oyen H, Demarest S, Klumbiene J, Regidor E, Helmert U, Jusot F, Dzurova D, Mackenbach JP. Comparative appraisal of educational inequalities in overweight and obesity among adults in 19 European countries. Int. J. Epidemiol. 2010;39(2):392–404. doi: 10.1093/ije/dyp329. [DOI] [PubMed] [Google Scholar]
  • 86.Corella D, Carrasco P, Sorli JV, Coltell O, Ortega-Azorin C, Guillen M, Gonzalez JI, Saiz C, Estruch R, Ordovas JM. Education modulates the association of the FTO rs9939609 polymorphism with body mass index and obesity risk in the Mediterranean population. Nutr. Metab. Cardiovasc. Dis. 2010 doi: 10.1016/j.numecd.2010.10.006. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Hardy R, Wills AK, Wong A, Elks CE, Wareham NJ, Loos RJ, Kuh D, Ong KK. Life course variations in the associations between FTO and MC4R gene variants and body size. Hum. Mol. Genet. 2010;19(3):545–552. doi: 10.1093/hmg/ddp504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Kaakinen M, Laara E, Pouta A, Hartikainen AL, Laitinen J, Tammelin TH, Herzig KH, Sovio U, Bennett AJ, Peltonen L, McCarthy MI, Elliott P, De Stavola B, Jarvelin MR. Life-course analysis of a fat mass and obesity-associated (fto) gene variant and body mass index in the northern finland birth cohort 1966 using structural equation modeling. Am. J. Epidemiol. 2010;172(6):653–655. doi: 10.1093/aje/kwq178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Hertel JK, Johansson S, Sonestedt E, Jonsson A, Lie RT, Platou CG, Nilsson PM, Rukh G, Midthjell K, Hveem K, Melander O, Groop L, Lyssenko V, Molven A, Orho-Melander M, Njolstad PR. FTO, Type 2 diabetes, and weight gain throughout adult life: A meta-analysis of 41,504 subjects from the scandinavian HUNT, MDC, and MPP studies. Diabetes. 2011 doi: 10.2337/db10-1340. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549–1555. doi: 10.1001/jama.295.13.1549. [DOI] [PubMed] [Google Scholar]
  • 91.Dempfle A, Hinney A, Heinzel-Gutenbrunner M, Raab M, Geller F, Gudermann T, Schafer H, Hebebrand J. Large quantitative effect of melanocortin-4 receptor gene mutations on body mass index. J. Med. Genet. 2004;41(10):795–800. doi: 10.1136/jmg.2004.018614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Stone S, Abkevich V, Russell DL, Riley R, Timms K, Tran T, Trem D, Frank D, Jammulapati S, Neff CD, Iliev D, Gress R, He G, Frech GC, Adams TD, Skolnick MH, Lanchbury JS, Gutin A, Hunt SC, Shattuck D. TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition. Hum. Mol. Genet. 2006;15(18):2709–2720. doi: 10.1093/hmg/ddl204. [DOI] [PubMed] [Google Scholar]
  • 93.Meyre D, Farge M, Lecoeur C, Proenca C, Durand E, Allegaert F, Tichet J, Marre M, Balkau B, Weill J, Delplanque J, Froguel P. R125W coding variant in TBC1D1 confers risk for familial obesity and contributes to linkage on chromosome 4p14 in the French population. Hum. Mol. Genet. 2008;17(12):1798–1802. doi: 10.1093/hmg/ddn070. [DOI] [PubMed] [Google Scholar]
  • 94.Lindgren CM, Heid IM, Randall JC, Lamina C, Steinthorsdottir V, Qi L, Speliotes EK, Thorleifsson G, Willer CJ, Herrera BM, Jackson AU, Lim N, Scheet P, Soranzo N, Amin N, Aulchenko YS, Chambers JC, Drong A, Luan J, Lyon HN, Rivadeneira F, Sanna S, Timpson NJ, Zillikens MC, Zhao JH, Almgren P, Bandinelli S, Bennett AJ, Bergman RN, Bonnycastle LL, Bumpstead SJ, Chanock SJ, Cherkas L, Chines P, Coin L, Cooper C, Crawford G, Doering A, Dominiczak A, Doney AS, Ebrahim S, Elliott P, Erdos MR, Estrada K, Ferrucci L, Fischer G, Forouhi NG, Gieger C, Grallert H, Groves CJ, Grundy S, Guiducci C, Hadley D, Hamsten A, Havulinna AS, Hofman A, Holle R, Holloway JW, Illig T, Isomaa B, Jacobs LC, Jameson K, Jousilahti P, Karpe F, Kuusisto J, Laitinen J, Lathrop GM, Lawlor DA, Mangino M, McArdle WL, Meitinger T, Morken MA, Morris AP, Munroe P, Narisu N, Nordstrom A, Nordstrom P, Oostra BA, Palmer CN, Payne F, Peden JF, Prokopenko I, Renstrom F, Ruokonen A, Salomaa V, Sandhu MS, Scott LJ, Scuteri A, Silander K, Song K, Yuan X, Stringham HM, Swift AJ, Tuomi T, Uda M, Vollenweider P, Waeber G, Wallace C, Walters GB, Weedon MN, Witteman JC, Zhang C, Zhang W, Caulfield MJ, Collins FS, Davey Smith G, Day IN, Franks PW, Hattersley AT, Hu FB, Jarvelin MR, Kong A, Kooner JS, Laakso M, Lakatta E, Mooser V, Morris AD, Peltonen L, Samani NJ, Spector TD, Strachan DP, Tanaka T, Tuomilehto J, Uitterlinden AG, van Duijn CM, Wareham NJ, Hugh W, Waterworth DM, Boehnke M, Deloukas P, Groop L, Hunter DJ, Thorsteinsdottir U, Schlessinger D, Wichmann HE, Frayling TM, Abecasis GR, Hirschhorn JN, Loos RJ, Stefansson K, Mohlke KL, Barroso I, McCarthy MI. Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet. 2009;5(6):e1000508. doi: 10.1371/journal.pgen.1000508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Heid IM, Jackson AU, Randall JC, Winkler TW, Qi L, Steinthorsdottir V, Thorleifsson G, Zillikens MC, Speliotes EK, Magi R, Workalemahu T, White CC, Bouatia-Naji N, Harris TB, Berndt SI, Ingelsson E, Willer CJ, Weedon MN, Luan J, Vedantam S, Esko T, Kilpelainen TO, Kutalik Z, Li S, Monda KL, Dixon AL, Holmes CC, Kaplan LM, Liang L, Min JL, Moffatt MF, Molony C, Nicholson G, Schadt EE, Zondervan KT, Feitosa MF, Ferreira T, Allen HL, Weyant RJ, Wheeler E, Wood AR, Estrada K, Goddard ME, Lettre G, Mangino M, Nyholt DR, Purcell S, Smith AV, Visscher PM, Yang J, McCarroll SA, Nemesh J, Voight BF, Absher D, Amin N, Aspelund T, Coin L, Glazer NL, Hayward C, Heard-Costa NL, Hottenga JJ, Johansson A, Johnson T, Kaakinen M, Kapur K, Ketkar S, Knowles JW, Kraft P, Kraja AT, Lamina C, Leitzmann MF, McKnight B, Morris AP, Ong KK, Perry JR, Peters MJ, Polasek O, Prokopenko I, Rayner NW, Ripatti S, Rivadeneira F, Robertson NR, Sanna S, Sovio U, Surakka I, Teumer A, van Wingerden S, Vitart V, Zhao JH, Cavalcanti-Proenca C, Chines PS, Fisher E, Kulzer JR, Lecoeur C, Narisu N, Sandholt C, Scott LJ, Silander K, Stark K, Tammesoo ML, Teslovich TM, Timpson NJ, Watanabe RM, Welch R, Chasman DI, Cooper MN, Jansson JO, Kettunen J, Lawrence RW, Pellikka N, Perola M, Vandenput L, Alavere H, Almgren P, Atwood LD, Bennett AJ, Biffar R, Bonnycastle LL, Bornstein SR, Buchanan TA, Campbell H, Day IN, Dei M, Dorr M, Elliott P, Erdos MR, Eriksson JG, Freimer NB, Fu M, Gaget S, Geus EJ, Gjesing AP, Grallert H, Grassler J, Groves CJ, Guiducci C, Hartikainen AL, Hassanali N, Havulinna AS, Herzig KH, Hicks AA, Hui J, Igl W, Jousilahti P, Jula A, Kajantie E, Kinnunen L, Kolcic I, Koskinen S, Kovacs P, Kroemer HK, Krzelj V, Kuusisto J, Kvaloy K, Laitinen J, Lantieri O, Lathrop GM, Lokki ML, Luben RN, Ludwig B, McArdle WL, McCarthy A, Morken MA, Nelis M, Neville MJ, Pare G, Parker AN, Peden JF, Pichler I, Pietilainen KH, Platou CG, Pouta A, Ridderstrale M, Samani NJ, Saramies J, Sinisalo J, Smit JH, Strawbridge RJ, Stringham HM, Swift AJ, Teder-Laving M, Thomson B, Usala G, van Meurs JB, van Ommen GJ, Vatin V, Volpato CB, Wallaschofski H, Walters GB, Widen E, Wild SH, Willemsen G, Witte DR, Zgaga L, Zitting P, Beilby JP, James AL, Kahonen M, Lehtimaki T, Nieminen MS, Ohlsson C, Palmer LJ, Raitakari O, Ridker PM, Stumvoll M, Tonjes A, Viikari J, Balkau B, Ben-Shlomo Y, Bergman RN, Boeing H, Smith GD, Ebrahim S, Froguel P, Hansen T, Hengstenberg C, Hveem K, Isomaa B, Jorgensen T, Karpe F, Khaw KT, Laakso M, Lawlor DA, Marre M, Meitinger T, Metspalu A, Midthjell K, Pedersen O, Salomaa V, Schwarz PE, Tuomi T, Tuomilehto J, Valle TT, Wareham NJ, Arnold AM, Beckmann JS, Bergmann S, Boerwinkle E, Boomsma DI, Caulfield MJ, Collins FS, Eiriksdottir G, Gudnason V, Gyllensten U, Hamsten A, Hattersley AT, Hofman A, Hu FB, Illig T, Iribarren C, Jarvelin MR, Kao WH, Kaprio J, Launer LJ, Munroe PB, Oostra B, Penninx BW, Pramstaller PP, Psaty BM, Quertermous T, Rissanen A, Rudan I, Shuldiner AR, Soranzo N, Spector TD, Syvanen AC, Uda M, Uitterlinden A, Volzke H, Vollenweider P, Wilson JF, Witteman JC, Wright AF, Abecasis GR, Boehnke M, Borecki IB, Deloukas P, Frayling TM, Groop LC, Haritunians T, Hunter DJ, Kaplan RC, North KE, O'Connell JR, Peltonen L, Schlessinger D, Strachan DP, Hirschhorn JN, Assimes TL, Wichmann HE, Thorsteinsdottir U, van Duijn CM, Stefansson K, Cupples LA, Loos RJ, Barroso I, McCarthy MI, Fox CS, Mohlke KL, Lindgren CM. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat. Genet. 2011;42(11):949–960. doi: 10.1038/ng.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Traurig M, Mack J, Hanson RL, Ghoussaini M, Meyre D, Knowler WC, Kobes S, Froguel P, Bogardus C, Baier LJ. Common variation in SIM1 is reproducibly associated with BMI in Pima Indians. Diabetes. 2009;58(7):1682–1689. doi: 10.2337/db09-0028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Ghoussaini M, Stutzmann F, Couturier C, Vatin V, Durand E, Lecoeur C, Degraeve F, Heude B, Tauber M, Hercberg S, Levy-Marchal C, Tounian P, Weill J, Traurig M, Bogardus C, Baier L, Michaud J, Froguel P, Meyre D. Analysis of the SIM1 contribution to polygenic obesity in the French population. Obesity (Silver Spring) 2010;18(8):1670–1675. doi: 10.1038/oby.2009.468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Pietri-Rouxel F, St John Manning B, Gros J, Strosberg AD. The biochemical effect of the naturally occurring Trp64-->Arg mutation on human beta3-adrenoceptor activity. Eur. J. Biochem. 1997;247(3):1174–1179. doi: 10.1111/j.1432-1033.1997.01174.x. [DOI] [PubMed] [Google Scholar]
  • 99.Cho YS, Go MJ, Kim YJ, Heo JY, Oh JH, Ban HJ, Yoon D, Lee MH, Kim DJ, Park M, Cha SH, Kim JW, Han BG, Min H, Ahn Y, Park MS, Han HR, Jang HY, Cho EY, Lee JE, Cho NH, Shin C, Park T, Park JW, Lee JK, Cardon L, Clarke G, McCarthy MI, Lee JY, Lee JK, Oh B, Kim HL. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat. Genet. 2009;41(5):527–534. doi: 10.1038/ng.357. [DOI] [PubMed] [Google Scholar]
  • 100.Santoro N, Perrone L, Cirillo G, Raimondo P, Amato A, Coppola F, Santarpia M, D'Aniello A, Miraglia Del Giudice E. Weight loss in obese children carrying the proopiomelanocortin R236G variant. J. Endocrinol. Invest. 2006;29(3):226–230. doi: 10.1007/BF03345544. [DOI] [PubMed] [Google Scholar]
  • 101.Reinehr T, Hebebrand J, Friedel S, Toschke AM, Brumm H, Biebermann H, Hinney A. Lifestyle intervention in obese children with variations in the melanocortin 4 receptor gene. Obesity (Silver Spring) 2009;17(2):382–389. doi: 10.1038/oby.2008.422. [DOI] [PubMed] [Google Scholar]
  • 102.Muller TD, Hinney A, Scherag A, Nguyen TT, Schreiner F, Schafer H, Hebebrand J, Roth CL, Reinehr T. 'Fat mass and obesity associated' gene (FTO): no significant association of variant rs9939609 with weight loss in a lifestyle intervention and lipid metabolism markers in German obese children and adolescents. BMC Med. Genet. 2008;9:85. doi: 10.1186/1471-2350-9-85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Grau K, Hansen T, Holst C, Astrup A, Saris WH, Arner P, Rossner S, Macdonald I, Polak J, Oppert JM, Langin D, Martinez JA, Pedersen O, Sorensen TI. Macronutrient-specific effect of FTO rs9939609 in response to a 10-week randomized hypo-energetic diet among obese Europeans. Int. J. Obes. (Lond) 2009;33(11):1227–1234. doi: 10.1038/ijo.2009.159. [DOI] [PubMed] [Google Scholar]
  • 104.Razquin C, Martinez JA, Martinez-Gonzalez MA, Bes-Rastrollo M, Fernandez-Crehuet J, Marti A. A 3-year intervention with a Mediterranean diet modified the association between the rs9939609 gene variant in FTO and body weight changes. Int. J. Obes. (Lond) 2010;34(2):266–272. doi: 10.1038/ijo.2009.233. [DOI] [PubMed] [Google Scholar]
  • 105.Mitchell JA, Church TS, Rankinen T, Earnest CP, Sui X, Blair SN. FTO genotype and the weight loss benefits of moderate intensity exercise. Obesity (Silver Spring) 2010;18(3):641–643. doi: 10.1038/oby.2009.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 2002;110(8):1093–1103. doi: 10.1172/JCI15693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Paz-Filho G, Wong ML, Licinio J. Ten years of leptin replacement therapy. Obes. Rev. 2011 doi: 10.1111/j.1467-789X.2010.00840.x. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
  • 108.Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999;282(16 ):1568–1575. doi: 10.1001/jama.282.16.1568. [DOI] [PubMed] [Google Scholar]
  • 109.Roubert P, Dubern B, Plas P, Lubrano-Berthelier C, Alihi R, Auger F, Deoliveira DB, Dong JZ, Basdevant A, Thurieau C, Clement K. Novel pharmacological MC4R agonists can efficiently activate mutated MC4R from obese patient with impaired endogenous agonist response. J. Endocrinol. 2010;207(2 ):177–183. doi: 10.1677/JOE-09-0336. [DOI] [PubMed] [Google Scholar]
  • 110.Rene P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HI, Farooqi IS, Valenzano KJ, Bouvier M. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. J. Pharmacol. Exp. Ther. 2010;335(3):520–532. doi: 10.1124/jpet.110.172098. [DOI] [PubMed] [Google Scholar]
  • 111.Hauner H, Meier M, Jockel KH, Frey UH, Siffert W. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics. 2003;13(8 ):453–459. doi: 10.1097/00008571-200308000-00003. [DOI] [PubMed] [Google Scholar]
  • 112.Hsiao DJ, Wu LS, Huang SY, Lin E. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenet. Genomics. 2009;19(9):730–733. doi: 10.1097/FPC.0b013e3283307cf1. [DOI] [PubMed] [Google Scholar]
  • 113.Grudell AB, Sweetser S, Camilleri M, Eckert DJ, Vazquez-Roque MI, Carlson PJ, Burton DD, Braddock AE, Clark MM, Graszer KM, Kalsy SA, Zinsmeister AR. A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology. 2008;135(4):1142–1154. doi: 10.1053/j.gastro.2008.07.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Aslan IR, Ranadive SA, Ersoy BA, Rogers SJ, Lustig RH, Vaisse C. Bariatric surgery in a patient with complete MC4R deficiency. Int. J. Obes. (Lond) 2011;35(3):457–461. doi: 10.1038/ijo.2010.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Aslan IR, Campos GM, Calton MA, Evans DS, Merriman RB, Vaisse C. Weight loss after Roux-en-Y gastric bypass in obese patients heterozygous for MC4R mutations. Obes. Surg. 2010 doi: 10.1007/s11695-010-0295-8. [Epub ahead of print] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Sarzynski MA, Jacobson P, Rankinen T, Carlsson B, Sjostrom L, Bouchard C, Carlsson LM. Associations of markers in 11 obesity candidate genes with maximal weight loss and weight regain in the SOS bariatric surgery cases. Int. J. Obes. (Lond) 2010 doi: 10.1038/ijo.2010.166. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
  • 117.Still CD, Wood GC, Chu X, Erdman R, Manney CH, Benotti PN, Petrick AT, Strodel WE, Mirshahi UL, Mirshahi T, Carey DJ, Gerhard GS. High allelic burden of four obesity SNPs is associated with poorer weight loss outcomes following gastric bypass surgery. Obesity (Silver Spring) 2011 doi: 10.1038/oby.2011.3. [Epub ahead of print] [DOI] [PubMed] [Google Scholar]
  • 118.Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk of complex disease. Curr. Opin. Genet. Dev. 2008;18(3):257–263. doi: 10.1016/j.gde.2008.07.006. [DOI] [PubMed] [Google Scholar]
  • 119.Sandholt CH, Sparso T, Grarup N, Albrechtsen A, Almind K, Hansen L, Toft U, Jorgensen T, Hansen T, Pedersen O. Combined analyses of 20 common obesity susceptibility variants. Diabetes. 2010;59(7):1667–1673. doi: 10.2337/db09-1042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Kooperberg C, LeBlanc M, Obenchain V. Risk prediction using genome-wide association studies. Genet. Epidemiol. 2010;34(7):643–652. doi: 10.1002/gepi.20509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Wei Z, Wang K, Qu HQ, Zhang H, Bradfield J, Kim C, Frackleton E, Hou C, Glessner JT, Chiavacci R, Stanley C, Monos D, Grant SF, Polychronakos C, Hakonarson H. From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. PLoS Genet. 2009;5(10):e1000678. doi: 10.1371/journal.pgen.1000678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Melchior C, Kiess W, Dittrich K, Schulz A, Schoneberg T, Korner A. Slim despite a genetic predisposition for obesity--influence of environmental factors as chance? A case report. Dtsch. Med. Wochenschr. 2009;134(20):1047–1050. doi: 10.1055/s-0029-1222565. [DOI] [PubMed] [Google Scholar]
  • 123.O'Rahilly S, Farooqi IS. Human obesity: a heritable neurobehavioral disorder that is highly sensitive to environmental conditions. Diabetes. 2008;57(11):2905–2910. doi: 10.2337/db08-0210. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Current Genomics are provided here courtesy of Bentham Science Publishers

RESOURCES